| Buffer free formulation for therapeutic use, comprises anti-cluster of differentiation antibody, water and surfactant, pharmaceutically acceptable excipients selected from sugar or amino acid or polyol or salt or surfactant, where sugar is trehalose, sucrose, mannitol or sorbitol | |
| 2023-08-12 | |
| 专利权人 | DR REDDY'S LAB LTD (REDY-C) |
| 申请日期 | 2023-08-12 |
| 专利号 | IN202341054214-A |
| 成果简介 | NOVELTY - Buffer free formulation comprises anti-cluster of differentiation (CD20) antibody, water and surfactant, where the pH of the anti-CD20 antibody formulation is maintained without any buffering agent. USE - Buffer free formulation for therapeutic use. ADVANTAGE - The buffer free formulation is a stable liquid/aqueous formulation at a pH of 5.0-6.5 and lyophilized as lyophilized powders, exhibit colloidal stability under accelerated conditions such as at 40℃ for two weeks, withstand thermal stress, shear stress, freeze thaw induced stress, and has viscosity less than 20 cP. |
| IPC 分类号 | A61K-039/395 ; A61K-047/26 ; A61K-009/08 ; C07K-016/28 |
| 国家 | 印度 |
| 专业领域 | 医药卫生 |
| 语种 | 英语 |
| 成果类型 | 专利 |
| 文献类型 | 科技成果 |
| 条目标识符 | http://119.78.100.226:8889/handle/3KE4DYBR/20830 |
| 专题 | 中国科学院新疆生态与地理研究所 |
| 作者单位 | DR REDDY'S LAB LTD (REDY-C) |
| 推荐引用方式 GB/T 7714 | RAJARAMAN S,MARIKANTY K R,SONI S,et al. Buffer free formulation for therapeutic use, comprises anti-cluster of differentiation antibody, water and surfactant, pharmaceutically acceptable excipients selected from sugar or amino acid or polyol or salt or surfactant, where sugar is trehalose, sucrose, mannitol or sorbitol. IN202341054214-A[P]. 2023. |
| 条目包含的文件 | 条目无相关文件。 | |||||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论